Insilico Announces Successful Completion of Phase 0 Microdose Trial and Initiates Phase I Clinical Trial for its First AI-discovered Anti-fibrotic Product Candidate with Novel Target
The double-blind, placebo managed single and a number of ascending dose Section I scientific trial will consider the protection, tolerability, ...
